查看購物車
  • Japanese
視網膜疾病市場（2025）：各國疾病盛行率數據
市場調查報告書
商品編碼
1928842

視網膜疾病市場（2025）：各國疾病盛行率數據

2025 Retinal Disease Model: Country-Level Disease Prevalence Data
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

Market Scope 的 "視網膜疾病市場（2025）" 報告提供了全球視網膜疾病真實規模的詳細國家層面分析。報告針對人口超過一百萬的國家，按年齡組提供了詳細的盛行率估算和五年預測。

此專有模型基於最新的臨床研究和全球人口統計預測，提供嚴謹且前瞻性的視網膜疾病分析，並可根據地區和疾病類別進行定制，以滿足特定的戰略需求。該報告幫助企業量化潛在患者群體，評估臨床和商業產品的目標市場，並了解疾病發生率和人口統計數據隨時間的變化。

目錄：

"視網膜疾病市場（2025）" 報告提供了228個人口超過一百萬的國家/地區按年齡組劃分的全面國家/地區特定患病率數據，從而全面展現了全球視網膜疾病的負擔。我們的覆蓋範圍涵蓋具有商業意義的大規模適應症，以及罕見的遺傳性疾病，從而為與當前市場和未來治療開發相關的患者群體提供統一的視角。

目標疾病包括：

  • 老年性黃斑部病變：早期AMD、晚期AMD、濕性AMD、地圖狀萎縮
  • 糖尿病視網膜病變：非增殖性糖尿病視網膜病變（輕度、中度、重度）、增殖性糖尿病視網膜病變（伴隨或不伴隨糖尿病黃斑水腫）、糖尿病黃斑水腫、威脅視力的糖尿病視網膜病變
  • 視網膜血管疾病：中心視網膜靜脈阻塞與視網膜靜脈分支阻塞
  • 其他視網膜疾病：近視性脈絡膜新生血管、非感染性後葡萄膜炎、視網膜剝離、視網膜裂孔、視網膜分隔符
  • 遺傳性視網膜疾病：視網膜色素變性、斯塔加特氏症、脈絡膜色素變性、萊伯先天性黑蒙、萊伯遺傳性視神經病變、全色盲、X連鎖青少年視網膜劈裂症及其他遺傳性視網膜疾病

研究方法：

Market Scope 利用專有的人口統計模型和最新的臨床研究來估算各國的疾病盛行率。我們的視網膜疾病模型整合了來自 130 多項同行評審的臨床和流行病學研究的數據，每項輸入都經過仔細評估，並根據研究設計、樣本量、年齡分層、地理相關性和範圍進行加權。這些數據與特定國家的人口結構和人口預測相一致，從而在不同市場中產生一致且可比較的盛行率估計值。

簡介目錄

Market Scope's "2025 Retinal Disease Model" delivers deep, country-level insight into the true scale of retinal disease worldwide, with detailed prevalence estimates and five-year forecasts by age group for every country with a population over one million.

Built on the latest clinical research and global demographic projections, this proprietary model provides a rigorous, forward-looking view of retinal disease-and can be customized by geography and disease category to match specific strategic needs. The model enables companies to quantify addressable patient populations, evaluate target markets for clinical- and commercial-stage products, and understand how disease volume and demographics are expected to evolve over time.

Contents:

The "2025 Retinal Disease Model" provides comprehensive, country-level prevalence data by age group across 228 countries with populations over one million, capturing the full global burden of retinal disease. Coverage spans large, commercially significant indications as well as rare inherited conditions, giving a unified view of patient populations relevant to both current markets and future therapeutic development.

Conditions covered include:

  • Age-related macular degeneration: early AMD, late AMD, wet AMD, and geographic atrophy
  • Diabetic retinal disease: non-proliferative DR (mild, moderate, severe), proliferative DR (with and without DME), diabetic macular edema, and vision-threatening DR
  • Retinal vascular disorders: central and branch retinal vein occlusion
  • Other retinal conditions: myopic choroidal neovascularization, non-infectious posterior uveitis, retinal detachment, retinal holes, and tears
  • Inherited retinal diseases: retinitis pigmentosa, Stargardt disease, choroideremia, Leber congenital amaurosis, Leber hereditary optic neuropathy, achromatopsia, X-linked juvenile retinoschisis, and other IRDs

Methodology:

Market Scope utilizes proprietary demographic models and the latest clinical research to estimate diseased populations at the country level. The retinal disease model integrates data from more than 130 peer-reviewed clinical and epidemiologic studies, with each input carefully evaluated and weighted based on study design, sample size, age stratification, geographic relevance, and scope. These data are then aligned with country-specific population structures and demographic projections to produce consistent, comparable prevalence estimates across markets.